China
Africa
Explore chapters and articles related to this topic
Crohn's Disease
Published in Charles Theisler, Adjuvant Medical Care, 2023
In another study, 18 patients with ulcerative colitis were given 3.2 gm of EPA and 2.16 gm of DHA daily for four months. The treatment group showed a 61% reduction in leukotriene B4 compared to a 2% reduction in the placebo group. Seven patients who received concurrent treatment with prednisone were able to reduce their medication by 50%.8
Reviewing the Available Herbal Resources for Treating Psoriasis: Safe and Alternative Way for Therapeutics
Published in Debarshi Kar Mahapatra, Cristóbal Noé Aguilar, A. K. Haghi, Applied Pharmaceutical Practice and Nutraceuticals, 2021
Shruti Dongare, Vaibhav Shende, Debarshi Kar Mahapatra
Traditionally, M. recutita is used in several therapies on skin rejuvenation, stress relief, and so on and is also employed in GI disorders. The byproduct of matricin is a non-oil extract component that is taken into medical applications for psoriasis and skin diseases. It is known to possess selective leukotriene B4 (LTB4) inhibitory potential.16,17
The Role of Platelet-Activating Factor in Endotoxin-Related Disease
Published in Helmut Brade, Steven M. Opal, Stefanie N. Vogel, David C. Morrison, Endotoxin in Health and Disease, 2020
Taco W. Kuijpers, Tom van der Poll
Within the GPCR superfamily, inflammation can be mediated through lipid metabolites other than PAF, e.g., the aforementioned leukotrienes, thromboxanes, and prostaglandins (14). For instance, the leukotrienes are biologically active 5-lipoxygenase products of arachidonic acid metabolism involved in the mediation of many of the inflammatory disorders in which PAF is believed to act. Leukotriene B4 is generated by many cell types and is a chemoattractant for granulocytes. The sulfidopeptide leukotrienes C4, D4, and E4 have been incriminated in allergic reactions and increase vascular permeability and constrict smooth muscle. Leukotrienes also exert their biological actions through specific GPCR interactions (see Table 1).
What happens to basophils and tryptase, LXA4 and CysLTs during aspirin desensitization?
Published in Journal of Asthma, 2023
Gülfem E. Çelik, Ömür Aydin, Deniz Güloğlu, Derya Seçil, Mehmet Melli, Figen Doğu, Aydan Ikinciogullari, Betül A. Sin, Yavuz Demirel, Zeynep Misirligil
Leukotriene B4 receptor (HBLTR-1) expression on total lymphocytes, CD3 + 45+, and CD15 + 45+ gates was analyzed using flow cytometry with whole-blood lysis (25,26). One hundred microliters of peripheral blood were put into 12 × 75-mm polystyrene tubes (Falcon Labware, Meylan Cedex, France) and incubated in the dark at room temperature for 15 min with appropriate monoclonal antibodies. Then, red blood cell lysis, leukocyte stabilization, and fixation were performed using Immunoprep A, B, and C solutions with a Coulter-Q-Prep Epics Immunology Workstation (Coulter Corb., 4235825-B, Hialeah, FL, USA) and analyzed using five-color staining flow cytometry (Cytomics FC500 Flow Cytometer, Beckman Coulter Inc. Miami, FL, USA) The monoclonal antibodies used in this study were CD45 PC5 (Beckman Coulter, Marseille, France), CD3 FITC (Beckman Coulter, Marseille, France), and CD15 FITC (Beckman Coulter, Marseille, France). Leukotriene B4 receptor (HBLTR-1) and PE (BD Pharmingen) were used as negative controls.
Acne vulgaris: new evidence in pathogenesis and future modalities of treatment
Published in Journal of Dermatological Treatment, 2021
PPARs are ligand-activated transcription factors that upregulate lipid synthesis. Certain leukotrienes are potent PPAR ligands, such as leukotriene B4 (LTB4). LTB4 is considered to be a major player in the development of tissue inflammation. Synthesis of LTB4 is controlled by the enzyme 5-lipoxygenase (5-LOX). Zileuton, an oral 5-LOX inhibitor that downregulates expression of LTB4 in sebaceous gland and inhibits PPAR-mediated lipogenesis (34), underwent a clinical trial for safety and efficacy in acne (NCT00098358) (35). The results of a phase 2 study (2016-000540-33), with the PPAR-γ modulator, N-acetyl-GED-0507-34-LEVO, in 1% and 2% gel in acne are awaited (36). Acebilustat (CTX-4430), a leukotriene A4 hydrolase inhibitor, is also under investigation (NCT02385760) in patients with moderate to severe acne (37).
The pharmacological management of asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS)
Published in Expert Opinion on Pharmacotherapy, 2020
Timothy E. Albertson, James A. Chenoweth, Skyler J. Pearson, Susan Murin
Leukotriene pathway modifiers including both leukotriene synthesis inhibitors and receptor antagonists are widely available and used in asthma and other atopic diseases. The cysteinyl leukotrienes (cys-LT) which include C4, D4 and E4 are formed by arachidonic acid precursors acted on by 5-lipoxygenase enzyme activity that then attract eosinophils and interact at cys-LT receptors on the outer plasma membrane of monocytes, macrophages, eosinophils, mast cells and smooth muscle cells of the airway [106]. Two agents that antagonize the cys-LT receptor (LRA) are available in the US and Europe (montelukast and zafirlukast) and pranlukast is also available in Japan. The second class of leukotriene pathway modulators is an inhibitor of the 5-lipoxygenase enzyme that inhibits the synthesis of both cysteinyl leukotrienes (LTC4, LTD4, and LTE4) and leukotriene B4 (LTB4) (zileuton).